• Nosheen Anjum KRL Hospital, Islamabad-Pakistan
  • Zahid Nabi KRL Hospital Islamabad


    Background: Recurrence of the primary kidney disease causing graft loss in an otherwise good functioning graft in post renal transplantation period is a well-known entity. Approximately 15% of the graft failure occurs secondary to recurrence of the primary glomerulonephritis in post renal transplant period. Regarding primary glomerulonephritis, almost 33–35% of patients suffering from primary membranous nephropathy (PMN), an organ specific auto-immune podocytopathy reach end stage renal disease (ESRD) and renal transplant is then the only treatment modality of choice for them. But, unfortunately 30–50% will experience the disease recurrence and 40–50% will end up with graft loss. The discovery of M-type anti phospholipase auto antibodies (APLA2R-ab) has changed the paradigm. Different remarkable studies are available in the literature that have concluded that APLA2R-ab titers if performed before the renal transplantation are helpful in predicting the disease recurrence and their titration in post-renal transplant period is clinically relevant to see the risk of disease recurrence and its progression, help in treatment monitoring and also to observe the treatment response in terms of complete or partial remission of the disease. Till now, there are no evidence-based guidelines available for the prevention of rPMN in post renal transplant period. The traditional treatment regimens beneficial for the management of PMN in native kidneys are associated with certain serious side effects in post renal transplant period. Rituximab, an anti-CD20 monoclonal antibody (anti CD20 mAb) has emerged as a promising treatment option for such patients. Conclusion: In conclusion an approach intending an early diagnosis of the rPMN by using the APLA2r levels in serum and its management by utilizing rituximab has proved worthy in minimizing the risk of allograft loss secondary to recurrence of PMN in post renal transplant period. However further studies are still awaited regarding the efficacy, dose and duration of the treatment.

Author Biography

Nosheen Anjum, KRL Hospital, Islamabad-Pakistan

Nephrology PGT,


Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;36(1): 11–21.

Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol 2005;16(5):1205–13.

El‐Zoghby ZM, Grande JP, Fraile MG, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy: Early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 2009;9(12):2800–7.

Hofstra JM, Beck LH, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6(6):1286–91.

Nawaz FA, Larsen CP, Troxell ML. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2013;62(5):1012–7.

Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011;26(8):2526–32.

Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011;22(6):1137–43.

Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS. Autoantibodies against phospholipase A2 receptor in korean patients with membranous nephropathy. PLoS One 2013;8(4):e62151.

Ponticelli C, Passerini P. Can prognostic factors assist therapeutic decisions in idiopathic membranous nephropathy? J Nephrol 2010;23(2):156–63.

Ponticelli C, Glassock RJ. Glomerular diseases: membranous nephropathy–a modern view. Clin J Am Soc Nephrol 2014;9(3):609–16.

Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 202;347(2):103–9.

Cosyns JP, Couchoud C, Pouteil-Noble C, Squifflet JP, Pirson Y. Recurrence of membranous nephropathy after renal transplantation: Probability, outcome and risk factors. Clin Nephrol 1998;50(3):144–53.

Monga G, Mazzucco G, Basolo B, Quaranta S, Motta M, Segoloni G, et al. Membranous glomerulonephritis (MGN) in transplanted kidneys: Morphologic investigation on 256 renal allografts. Mod Pathol 1993;6(3):249–8.

Truong L, Gelfand J, D'Agati V, Tomaszewski J, Appel G, Hardy M, et al. De novo membranous glomerulonephropathy in renal allografts: A report of ten cases and review of the literature. Am J Kidney Dis 1989;14(2):131–44.

Berger BE, Vincenti F, Biava C, Amend WJ Jr, Feduska N, Salvatierra O Jr. De novo and recurrent membranous glomerulopathy following kidney transplantation. Transplantation 1983;35(4):315–9.

Morzycka M, Croker Jr BP, Siegler HF, Tisher CC. Evaluation of recurrent glomerulonephritis in kidney allografts. Am J Med 1982;7294):588–98.

Xipell M, Rodas LM, Villarreal J, Molina A, Reinoso-Moreno J, Blasco M, et al. The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation. Clin Kidney J 2018;11(3):422–8.

Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep 2015;5(1):1–9.

De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol 2017;28:421–30.

Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011;364(7):616–26.

Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010;63:496–8.

Kattah A, Ayalon R, Beck LH Jr, Sethi S, Sandor DG, Cosio FG, et al. Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy. Am J Transplant 2015;15:1349–59.

Quintana LF, Blasco M, Seras M, Pérez NS, Lòpez-Hoyos M, Villarroel P, et al. Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy. Transplantation 2015;99(8):1709–14.

Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int 2017;91(2):304–4.

Gupta G, Fattah H, Ayalon R, Kidd J, Gehr T, Quintana LF, et al. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. Clin Transplant 2016;30(4):461–9.

Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, et al. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. Nephrol Dial Transplant 2014;29:2334–42.

Debiec H, Ronco P. Immune response against autoantigen PLA2R Is not gambling: implications for pathophysiology, prognosis, and therapy. J Am Soc Nephrol 2016;27:1275–7.

Debiec H, Martin L, Jouanneau C, Dautin G, Mesnard L, Rondeau E, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and de novo membranous nephropathy. Am J Transplant 2011;11(10):2144–52.

Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011;364:689–90.

Tomas NM, Beck Jr LH, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371(24):2277–87.

Dabade TS, Grande JP, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant 2008;8:1318–22.

Marcen R, Mampaso F, Teruel JL, Rivera ME, Orofino L, Navarro-Antolin J, et al. Membranous nephropathy: recurrence after kidney transplantation. Nephrol Dial Transplant 1996;11:1129–33.

Poduval RD, Josephson MA, Javaid B. Treatment of de novo and recurrent membranous nephropathy in renal transplant patients. Semin Nephrol 2003;23(4):392–9.

Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923–4.

Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010;5:2188–98.

Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1416–25.

Gallon L, Chhabra D. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 2006;6:3017–21.

Sprangers B, Lefkowitz GI, Cohen SD, Stokes MB, Valeri A, Appel GB, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010;5(5):790–7.

Glassock RJ, Feldman D, Reynolds ES, Dammin GJ, Merrill JP. Human renal isografts: a clinical and pathologic analysis. Medicine (Baltimore) 1968;47(5):411–54.

Moroni G, Gallelli B, Quaglini S, Leoni A, Banfi G, Passerini P, et al. Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN). Nephrol Dial Transplant 2010;25:3408–15.

Cattran D. Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol 2005;16:1188–94.